DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160777

Empagliflozin: the latest SGLT2 inhibitor on the block

Sangeeta Bhanwra, Kaza Ahluwalia

Abstract


Empagliflozin, the latest SGLT2 inhibitor is a selective, highly potent and competitive inhibitor of SGLT2 leading to the lowering of plasma glucose level by letting the sugar pass in the urine. It has a good safety and efficacy profile and is quite convenient to use for the patient as well, except for some increase in the urinary and genital mycotic infections in the recipients. 


Keywords


Empagliflozin, Blood sugar, SGLT 2 inhibitor

Full Text:

PDF

References


Temelkova-Kurktschiev T, Stefanov T. Lifestyle and genetics in obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes. 2012;120(1):1-6.

Jabbour SA. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med. 2014;126(1):111-7.

US Food Drug and administration. FDA news release: FDA approves Invokana to treat type 2 diabetes, March 29, 2013 [cited 28 January 2016]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm

US Food Drug and administration. FDA news release: FDA approves Farxiga to treat type 2 diabetes, January 8, 2014 [cited 28 January 2016]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm

US Food Drug and administration. FDA news release: FDA approves Jardiance to treat type 2 diabetes, August 1, 2014 [cited 28 january 2016]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.

Bays H. Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther. 2013;4(2):195-220.

Grempler R, Thomas L, Eckhardt M. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83-90.

Heise T, Seewaldt-Becker E, Macha S. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type-2 diabetes. Diabetes Obes Metab. 2013;15(7):613-21.

Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59.

Seman L, Macha S, Nehmiz G. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152-61.

Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, Negishi T. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213-9.

Seman L, Macha S, Nehmiz G. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152-61.

Macha S, Rose P, Mattheus M. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2013.

Macha S, Mattheus M, Halabi A. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2013.

Macha S, Dieterich S, Mattheus M. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:132-40.

Brand T, Macha S, Mattheus M. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29:889-99.

Macha S, Mattheus M, Pinnetti S. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab. 2012;1:1-7.

Macha S, Rose P, Mattheus M. Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15:316-23.

Macha S, Sennewald R, Rose P. Lack of clinically relevant drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226-35.

Macha S, Lang B, Pinnetti S. Lack of pharmacokinetic interaction between the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin and simvastatin in healthy volunteers. J Diabetes Investig. 2012;3:228.

Macha S, Mattheus M, Pinnetti S. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig. 2013;33:351-7.

Heise T, Seman L, Macha S. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4:331-45.

McGill JB. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Ther. 2014;5(1):43-63.